University of Oxford

Genentech has entered an exclusive collaboration with OMass Therapeutics to develop oral small molecules targeting a first-in-class inflammatory bowel disease target, with $20 million upfront and over $400 million in potential milestone payments.

OrganOx, the Oxford-based medtech company behind pioneering liver perfusion technology, has been acquired by Terumo Corporation for approximately $1.5 billion.

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.

The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya.

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

Two independent studies demonstrate that intranasal COVID-19 vaccination induces robust mucosal immunity, including durable IgA responses and tissue-resident memory T cells in the respiratory tract, which intramuscular vaccination fails to achieve.

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.